Literature DB >> 9873192

Nocturnal TSH surge and TRH test response in the evaluation of thyroid axis in hypothalamic pituitary disorders in childhood.

L Gruñeiro-Papendieck1, A Chiesa, A Martínez, J J Heinrich, C Bergadá.   

Abstract

We studied, by means of TSH nocturnal secretion and TRH test, 42 children (4.2-19.9 years) with hypothalamic pituitary disorders and 24 healthy euthyroid children (5.7-15.4 years) as control group. Patients were divided according to their serum values of FT4 in group 1 (n = 27) with FT4 >/=10.3 pmol/l and group 2 (n = 15) with FT4 <10.3 pmol/l. TSH was measured by immunoradiometric assay. TSH nadir, TSH peak and TSH surge were calculated. Both groups differed significantly from control group in TSH surge values: group 1 (p < 0. 05), group 2 (p < 0.01). TRH test was abnormal in 11/27 patients of group 1 and 10/15 patients of group 2. In group 1, 7 patients had normal tests, 2 had abnormalities in both tests, 9 had only TSH nocturnal surge altered and 9 showed only TRH alterations. All patients of group 2 presented thyroid axis abnormalities. In conclusion, in patients with hypothalamic pituitary disorders with low FT4, no further investigation is required to demonstrate thyroid axis alterations, however in patients with normal FT4, nocturnal TSH secretion and TRH test may be required to evidence thyroid abnormalities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873192     DOI: 10.1159/000023286

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  2 in total

Review 1.  Endocrine manifestations of craniopharyngioma.

Authors:  Isil Halac; Donald Zimmerman
Journal:  Childs Nerv Syst       Date:  2005-07-27       Impact factor: 1.475

2.  A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction.

Authors:  Luciani R Carvalho; Kathryn S Woods; Berenice B Mendonca; Nathalie Marcal; Andrea L Zamparini; Stefano Stifani; Joshua M Brickman; Ivo J P Arnhold; Mehul T Dattani
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.